Vistagen Therapeutics, Inc. VTGN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Vistagen Therapeutics, Inc. (VTGN) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$59M, a net margin of -2475.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -122%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
About Vistagen Therapeutics
Vistagen Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2017 to $1M in 2026, growth of about 0.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 447% over three years (dilution for shareholders). It spends 4332% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $1M | $486000 | $1M | -$227000 | $1M | — | — | — | $0 | $1M |
| Net income | -$59M | -$70M | -$51M | -$29M | -$59M | -$48M | -$11M | -$12M | -$25M | -$14M | -$10M |
| Free cash flow | — | — | — | -$26M | -$50M | -$45M | — | — | -$15M | -$9M | -$8M |
| EPS (diluted) | $-1.36 | $-1.83 | $-1.67 | $-1.52 | $-8.51 | $-7.38 | — | — | $-0.90 | $-1.12 | $-1.54 |
| Net margin | -2475.6% | -5491.3% | -10579.8% | -2759.6% | 26100.4% | -4306.8% | — | — | — | — | -820.4% |
| ROIC | — | -155.8% | -61.5% | -22.4% | -316.6% | -55.7% | — | — | -272.0% | -160.9% | -1207.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $1.00, 454% above the current price; targets range from $1.00 to $1.00; the consensus rating is “Hold”; expected EPS is $-1.48 for the fiscal year ending March 31, 2027.
Frequently asked questions
Is Vistagen Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Vistagen Therapeutics pay a dividend?
Not currently.
Is Vistagen Therapeutics a good stock to buy?
We do not give buy or sell advice. Vistagen Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.